Moleculin Biotech is trading at $7.92, down 6.38%, as broader risk-off pressure weighs on shares.
- Interim results showed remission rates of 43% and 36% in the Annamycin arms, versus 12% for placebo; the monitoring committee recommended continuing the trial unchanged.
- Shares showed premarket strength after the results but fell during the session. Reuters reported a sharp U.S. selloff amid investor concerns about AI-related regulation and data-center expansion; biotech ETF XBI was down 5.19%.